Since its historic FDA approval in March 2024 as the first medication for MASH, Madrigal’s Rezdiffra has handily beat Wall Street’s sales projections for the fourth straight quarter. More: Madrigal's Rezdiffra, the first-ever MASH drug, beats sales projections for 4
read moreWhile Amgen’s legacy products are thriving, those gained from the company’s $27.8 billion buyout of Horizon Therapeutics in 2023 are struggling, especially blockbuster eye disease treatment Tepezza, which saw a 17% sequential decline in the first quarter. More: As Amgen's
read moreAmid the launch of its nonopioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management. More: As Journavx rollout begins, Vertex kicks off unbranded pain campaign with NFL alum Alex Smith Source: fierce
read moreReductions in staff at the FDA are putting pressure on biotech companies, especially those strapped for cash, and could lead to more M&A activity, according to Andrew Goodman, a partner in the M&A practice at business law firm Paul Hastings.
read moreJust as Eli Lilly appeared to be gaining an edge over its metabolic medicine rival Novo Nordisk in the U.S. obesity market, Novo has locked in a new formulary access deal that could give its star weight loss drug Wegovy
read more
Application seeks reduced infusion frequency to support patient flexibility More: Leqembi dosing proposal for Alzheimer’s treatment validated by MHRA Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals